Cipla Australia Pty Ltd, Pharmaceutical Import Profile — Australia (DGFT 2022–2026)

Name: Cipla Australia Pty Ltd, Pharmaceutical Import Records from India — 3 Products, $2.9M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Cipla Australia Pty Ltd, — Pharmaceutical Importer Profile (2026) | 3 Products, $2.9M Trade | TransData Nexus

Cipla Australia Pty Ltd,

Pharmaceutical Importer · Australia · Respiratory Focus · $2.9M Total Trade · DGFT Verified

Cipla Australia Pty Ltd, is a pharmaceutical importer based in Australia with a total trade value of $2.9M across 3 products in 2 therapeutic categories. Based on 58 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Cipla Australia Pty Ltd, sources from 1 verified Indian supplier, with Cipla Limited accounting for 100.0% of imports.

Cipla Australia Pty Ltd, — Import Portfolio & Supplier Network

Cipla Australia Pty Ltd, import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Cipla Australia Pty Ltd,?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Cipla Limited	$2.7M	309	100.0%

Cipla Australia Pty Ltd, sources from 1 verified Indian supplier across 142 distinct formulations. The sourcing is highly concentrated — Cipla Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Cipla Australia Pty Ltd, Import?

Formulation	Value	Ships
Fluticasone + salmeterol cipla 250/25	$400.0K	8
Entac 0.5 MG tablets ( entecavir)	$200.0K	4
Salbutamol cipla 5MG/ 2.5ML (as sulfate)	$164.6K	8
Fluticasone salmeterol ciphaler 250/50	$150.0K	3
Fluticasone + salmeterol cipla 250/25 hfa inhaler (fluticasone propionate 250mcg + salmeterol xinafoate 25mcg	$104.4K	3
Fluticasone + salmetrol cipla 125 /25	$100.0K	2
Fluticasone + salmeterol cipla 250/25 hfa inhaler (salmeterol xinafoate 25 MCG+fluticasone propionate 250mcg inhaler)	$100.0K	2
Cipla pain relief paracetamol +	$92.3K	8
Cipla etoricoxib 60 MG tablets	$78.9K	2
Salbutamol cipla 5 MG/2.5ML ( as	$69.3K	5
Fluticasone cipla inhaler 250 MCG	$59.0K	3
Tadacip 20 MG tablet (tadalafil) .	$55.5K	2
Salbutamol cipla 5MG/ 2.5ML (as sulfate) inhalation ampoules. (inv.qty. 24000 Pack 6 x 5 x 2.5 ML =720000	$55.2K	3
Tadalis 20 MG flim coated tablets	$53.2K	4
Cipla pregabalin 300 MG capsules	$50.0K	1

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Fluticasone	Respiratory	$1.4M	29	0.7%	11
2	Salmeterol	Respiratory	$950.0K	19	1.3%	6
3	Lenalidomide	Advanced Oncology	$500.0K	10	0.1%	14

Cipla Australia Pty Ltd, imports 3 pharmaceutical products across 2 categories into Australia totaling $2.9M.

Cipla Australia Pty Ltd, — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Cipla Australia Pty Ltd is an Australian proprietary company, limited by shares, registered on 10 July 2008, with the Australian Company Number (ACN) 132 155 063 and the Australian Business Number (ABN) 46 132 155 063. The company is headquartered in Victoria, Australia, with a registered address in South Melbourne, Victoria 3205. Initially incorporated as Meditab Specialities Pty Ltd, it underwent a name change to Cipla-Oz Pty Ltd on 8 March 2011, and subsequently to Cipla Australia Pty Ltd on 8 February 2013.

As a subsidiary of Cipla Limited, a prominent Indian pharmaceutical company, Cipla Australia Pty Ltd serves as the Australian arm of its parent company. Cipla Limited, headquartered in Mumbai, India, is renowned for its extensive range of pharmaceutical products across various therapeutic categories. In Australia, Cipla Australia Pty Ltd operates as a pharmaceutical importer and distributor, focusing on the importation and distribution of finished pharmaceutical formulations. The company's role in the Australian pharmaceutical distribution network involves sourcing medications from its parent company and other suppliers, ensuring compliance with local regulatory standards, and facilitating the availability of these products to healthcare providers and patients across the country.

2Distribution Network

Specific details regarding Cipla Australia Pty Ltd's warehouse locations and logistics capabilities are not publicly disclosed. However, as a subsidiary of Cipla Limited, it is reasonable to infer that the company leverages the established distribution infrastructure of its parent. Cipla Limited operates advanced manufacturing facilities in India, including locations in Goa and Baddi, Himachal Pradesh, which are likely utilized for the production and export of pharmaceutical products to Australia. Cipla Australia Pty Ltd's geographic coverage primarily encompasses Australia, ensuring that imported pharmaceutical products are distributed to various regions within the country. The company's logistics operations are expected to adhere to Australian standards for pharmaceutical distribution, ensuring the safe and efficient delivery of products to meet the needs of the Australian healthcare sector.

3Industry Role

Cipla Australia Pty Ltd functions as a pharmaceutical importer and distributor within Australia's pharmaceutical supply chain. Its primary role involves sourcing finished pharmaceutical formulations from its parent company, Cipla Limited, and other suppliers, and ensuring their availability in the Australian market. The company is not classified as a wholesaler, parallel importer, hospital supplier, or logistics intermediary; rather, it operates as a direct importer and distributor of pharmaceutical products. By importing and distributing medications, Cipla Australia Pty Ltd plays a crucial role in enhancing the accessibility of a diverse range of pharmaceutical products to healthcare providers and patients across Australia.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Cipla Australia Pty Ltd,

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Cipla Australia Pty Ltd exhibits a high degree of supplier concentration, with 100% of its pharmaceutical imports sourced from a single supplier, Cipla Limited. This exclusive sourcing strategy indicates a strategic partnership between the Australian subsidiary and its parent company, facilitating streamlined procurement processes and potentially favorable terms. The shipment data reveals a substantial volume of imports, with a total import value of $2.9 million USD across 58 shipments, predominantly consisting of three products: Fluticasone, Salmeterol, and Lenalidomide. This concentration suggests a stable and reliable supply chain relationship, as Cipla Australia Pty Ltd relies entirely on Cipla Limited for its pharmaceutical imports. While this single-source dependency may offer operational efficiencies, it also presents a risk in the event of supply chain disruptions or changes in the supplier's circumstances.

2Supply Chain Resilience

Cipla Australia Pty Ltd's supply chain resilience is closely tied to its exclusive sourcing arrangement with Cipla Limited. The company's import portfolio comprises 142 unique pharmaceutical formulations, indicating a diverse range of products sourced from its parent company. However, the absence of backup suppliers for these products suggests a potential vulnerability in the supply chain. In the event of disruptions affecting Cipla Limited's production or export capabilities, Cipla Australia Pty Ltd may face challenges in maintaining a consistent supply of these medications. Additionally, the company's reliance on a single supplier may limit its ability to adapt to changes in market demand or to diversify its product offerings. To enhance supply chain resilience, Cipla Australia Pty Ltd may consider exploring alternative sourcing options or establishing contingency plans to mitigate potential risks associated with its current supply chain structure.

Importing Pharmaceuticals into Australia — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Australia

1Regulatory Authority & Framework

In Australia, the regulation of pharmaceutical imports is overseen by the Therapeutic Goods Administration (TGA), an agency within the Department of Health. The TGA is responsible for ensuring the safety, efficacy, and quality of therapeutic goods, including medicines, medical devices, and biological products. The primary legislation governing pharmaceutical imports is the Therapeutic Goods Administration Act 1989, which outlines the regulatory framework for the importation, manufacturing, and supply of therapeutic goods in Australia. Under this act, all therapeutic goods must be entered in the Australian Register of Therapeutic Goods (ARTG) before they can be legally imported and supplied in Australia. (tga.gov.au)

2Import Licensing & GMP

To import therapeutic goods into Australia, companies must comply with the requirements set by the TGA. This includes ensuring that all imported medicines are included in the ARTG, which serves as the official record of therapeutic goods approved for supply in Australia. The TGA requires that overseas manufacturers hold a valid Good Manufacturing Practice (GMP) certificate from a recognized regulatory authority, such as the European Medicines Agency (EMA) or the World Health Organization (WHO), to demonstrate compliance with international manufacturing standards. Additionally, importers must obtain the necessary import licenses and permits, particularly when dealing with controlled substances, to ensure adherence to Australian regulations. (tga.gov.au)

Cipla Australia Pty Ltd, — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Cipla Australia Pty Ltd's product strategy focuses on importing pharmaceutical formulations in the respiratory and advanced oncology therapeutic categories. The company's top three imported products—Fluticasone, Salmeterol, and Lenalidomide—align with these therapeutic areas, with respiratory products accounting for 82.8% of imports and advanced oncology products comprising 17.2%. This strategic focus is likely driven by the significant demand for treatments in these areas within the Australian healthcare market. Respiratory conditions, such as asthma and chronic obstructive pulmonary disease (COPD), are prevalent in Australia, necessitating a steady supply of effective medications. Similarly, the growing incidence of cancer has increased the need for advanced oncology treatments, positioning Cipla Australia Pty Ltd to meet these critical healthcare needs.

2Sourcing Profile

Cipla Australia Pty Ltd's sourcing strategy is centered on importing generic pharmaceutical formulations from its parent company, Cipla Limited. The company's portfolio includes a diverse range of 142 unique formulations, indicating a broad approach to meeting various therapeutic needs. By sourcing from Cipla Limited, Cipla Australia Pty Ltd benefits from the parent company's established manufacturing capabilities and adherence to international quality standards. This sourcing strategy enables the Australian subsidiary to offer a wide array of affordable and effective medications to the Australian market, leveraging the strengths of its parent company's research and development, manufacturing, and regulatory compliance expertise

Frequently Asked Questions — Cipla Australia Pty Ltd,

What products does Cipla Australia Pty Ltd, import from India?

Cipla Australia Pty Ltd, imports 3 pharmaceutical products across 2 categories. Top imports: Fluticasone ($1.4M), Salmeterol ($950.0K), Lenalidomide ($500.0K).

Who supplies pharmaceuticals to Cipla Australia Pty Ltd, from India?

Cipla Australia Pty Ltd, sources from 1 verified Indian suppliers. The primary supplier is Cipla Limited (100.0% of imports, $2.7M).

What is Cipla Australia Pty Ltd,'s total pharmaceutical import value?

Cipla Australia Pty Ltd,'s total pharmaceutical import value from India is $2.9M, based on 58 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Cipla Australia Pty Ltd, focus on?

Cipla Australia Pty Ltd, imports across 2 categories. The largest: Respiratory (82.8%), Advanced Oncology (17.2%).

Get Full Cipla Australia Pty Ltd, Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.